Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Circulation. 2011 Jan 4;123(1):39-45. doi: 10.1161/CIRCULATIONAHA.110.981068. Epub 2010 Dec 20.
Despite evidence supporting the use of aspirin, β-blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering therapies in eligible patients, adoption of these secondary prevention measures after coronary artery bypass grafting has been inconsistent. We sought to rigorously test on a national scale whether low-intensity continuous quality improvement interventions can be used to speed secondary prevention adherence after coronary artery bypass grafting.
A total of 458 hospitals participating in the Society of Thoracic Surgeons National Cardiac Database and treating 361 328 patients undergoing isolated coronary artery bypass grafting were randomized to either a control or an intervention group. The intervention group received continuous quality improvement materials designed to influence the prescription of the secondary prevention medications at discharge. The primary outcome measure was discharge prescription rates of the targeted secondary prevention medications at intervention versus control sites, assessed by measuring preintervention and postintervention site differences. Prerandomization treatment patterns and baseline data were similar in the control (n=234) and treatment (n=224) groups. Individual medication use and composite adherence increased over 24 months in both groups, with a markedly more rapid rate of adherence uptake among the intervention hospitals and a statistically significant therapy hazard ratio in the intervention versus control group for all 4 secondary prevention medications.
Provider-led, low-intensity continuous quality improvement efforts can improve the adoption of care processes into national practice within the context of a medical specialty society infrastructure. The findings of the present trial have led to the incorporation of study outcome metrics into a medical society rating system for ongoing quality improvement.
尽管有证据支持在符合条件的患者中使用阿司匹林、β受体阻滞剂、血管紧张素转换酶抑制剂和降脂治疗,但在冠状动脉旁路移植术后采用这些二级预防措施的情况并不一致。我们旨在严格检验在全国范围内,低强度持续质量改进干预措施是否可用于加快冠状动脉旁路移植术后的二级预防措施的依从性。
共有 458 家参与胸外科医生学会国家心脏数据库的医院和治疗 361328 例单独进行冠状动脉旁路移植术的患者被随机分为对照组或干预组。干预组接受旨在影响出院时开具二级预防药物的持续质量改进材料。主要结局指标是通过测量干预前和干预后站点差异,评估干预与对照组出院时开具目标二级预防药物的处方率。在对照组(n=234)和治疗组(n=224)中,随机分组前的治疗模式和基线数据相似。两组的个体药物使用和综合依从性在 24 个月内均增加,干预组的依从性增加速度明显更快,干预组与对照组相比,所有 4 种二级预防药物的治疗风险比均具有统计学意义。
在医学专业学会基础设施的背景下,以提供者为导向、低强度的持续质量改进工作可以将护理流程的采用推广到全国实践中。本试验的结果导致将研究结果指标纳入医学学会的持续质量改进评级系统中。